Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NicVAX dose-ranging study in smokers
NCT00218413Phase 2Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Oct 2004
- Primary completion
- Aug 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NicVAX in nicotine dependence, sponsored by Nabi Biopharmaceuticals. Started Oct 2004; status: completed.
02
Drugs
NicVAX
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00218413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00218413.